Robert Morris
Robert Morris's Latest Posts
BST Trade Alert – October 8, 2015
Recommendation: Buy Anthera Pharma (NASDAQ: $ANTH) up to $7.00 per share. About the Company: Anthera Pharmecuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious and life-threatening diseases, including lupus, IgA nephropathy, and exocrine insufficiency due to cystic fibrosis. The company focuses on treatments and medicines with current unmet needs. Anthera […]
Biotech Market Update – October 2, 2015
Biotech Market Update It’s been an ugly week for biotech companies. You may have heard Hillary Clinton’s now infamous tweet, “Price gouging like this in the specialty drug market is outrageous. Tomorrow I’ll lay out a plan to take it on” that sent the market into a tailspin. Overnight, Biotech ETFs were down more than […]
BST Trade Alert – September 25, 2015
Recommendation: Buy OncoMed Pharmacueticals (NASDAQ: $OMED) up to $16.00 per share. About the Company: OncoMed is a clinical-stage company that researches and develops anti-cancer stem cell and immuno-oncology therapeutics. OMED has seven anti-product candidates in clinical development. OncoMed was founded with a focus on cancer stem cells which are a subpopulation of cells in a […]
BST Position Update – September 10, 2015
. . . . New Link Genetics (NASDAQ: $NLNK) – Buy up to $50.00 NLNK recently announced that their Phase 3 clinical study for VSV-ZEBOV is expected to meet its primary endpoint. It is exciting times for the company, as the vaccine will more than likely end up in consumer hands. This of course also […]
BST Trade Alert – September 4, 2015
Recommendation: Buy NewLink Genetics (NASDAQ: $NLNK) up to $50.00 per share. About the Company: NewLink Genetics was established in 1999 and focuses on immunotherapy for cancer treatment. When the company first started, they were focused on either the ability of a tumor to suppress the immune system or the immune system itself, being unable to […]
BST Position Update – August 31, 2015
. . . . Macrocure (NASDAQ: $MCUR) – Sell MCUR recently announced that their Phase 3 clinical study (MC-105) for venous leg ulcers (VLU) is not expected to meet its primary endpoint. Needless to say, that’s a major disappointment given the data they already had going into this clinical trial. The company is scrambling to […]
BST Position Update – June 11, 2015
. . . . Progenics Pharmaceuticals (NASDAQ: $PGNX) – Hold Progenics lead drug, Relistor, recently received approval from the European Commission to treat opioid-induced constipation (OIC) in all adult patients when response to laxative therapy has not been sufficient. They also received an additional year of marketing protection. The news seems to have triggered a […]
BST Trade Alert – June 9, 2015
Recommendation: Buy Celldex Therapeutics $NASDAQ: CLDX up to $28.00 per share. About the Company: Celldex believes the best way to treat and destroy many of the worst diseases is by harnessing the power of the immune system. They seek to leverage the power of the immune system’s response by combining therapeutic approaches to maximize the […]
BST Trade Alert – May 20, 2015
Recommendation: Buy Progenics Pharmaceuticals $NASD: PGNX up to $6.00 per share. About the Company: Progenics’ goal is to become a preeminent oncology company focused on developing innovative drugs to improve the lives of prostate cancer patients. Their pipeline includes therapeutic and diagnostic candidates in pre-clinical through late-stage development. They have one treatment, RELISTOR, that is approved […]
BST Trade Alert – April 24, 2015
Recommendation: Buy POZEN ($NASD: POZN) up to $9.00 per share. About the Company: POZEN calls themselves a ‘progressive pharmaceutical company’. They develop products to address unmet medical needs. They primarily develop drugs to treat pain and pain-related conditions by combining existing drug therapies that result in superior patient outcomes. Many of POZN’s developments combine aspirin with […]
